Journal of Hepatology

Article	Citations
Reply to: ‘Exploring hepatocellular carcinoma risks in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe’	2620
JHEP at a glance (October 2024)	1545
Multiplex immunostaining and transcriptomic profiling identify novel immune cell markers for non-alcoholic steatohepatitis and primary sclerosing cholangitis	1246
Non-alcoholic fatty liver disease features a reduced reverse polyunsaturated fatty acid transport (free fatty acids/high-density lipoprotein) from the periphery to the liver	1110
Preclinical pharmacology of low molecular weight GLP-1 receptor agonist XW014	1084
The anti-fibrotic efficacy of Adelmidrol depends in the level of hepatic PPAR gama	962
The gut (and its microbiota)-liver axis in liver disease associated with alpha-1-antitrypsin deficiency	864
Viral like particle analysis shows changes with PPIs and may be more sensitive than metagenomics to study PPI modulation of virome in cirrhosis	324
Gut-liver crosstalk in hepatocellular carcinoma and non-selective beta-blockers: is there a link?	320
Implementation of HCV screening in the 1969–1989 birth-cohort undergoing COVID-19 vaccination: a pivotal study in Italy	314
Outcomes between surgical resection and transarterial chemoembolization in patients with multifocal BCLC-A and Child-Pugh B	301
Liver complications in greek patients with sickle cell disease: a multicenter retrospective analysis from eight thalassemia and sickle cell units across Greece	293
Performance of a p-SWE method implemented on a new ultrasound system for predicting advanced liver fibrosis	281
Multiplexed digital spatial protein profiling reveals potential non-invasive biomarkers to predict advanced fibrosis	273
Altered gut barrier integrity as a mediator of host-microbiome interactions in diabetic patients with advanced Non-alcoholic fatty liver disease	264
Eliminating viral hepatitis one island at a time-the Hainan experience	253
Causes of death by fibrosis stage in 959 biopsy-proven NAFLD patients	253
Prevalence and predictors of HDV viremia in anti-HDV positive patients of the HEllenic multicenter ReAl-life CLInical Study (HERACLIS-HDV)	243
Assessing progress towards achieving regional hepatitis B control goal-nationwide serosurvey among children, Uzbekistan, 2022	241
PNPLA3 rs738409 G allele increases the risk of liver cirrhosis in SERPINA1 MZ heterogygotes	231
The health economic outcomes of trial ACTG5360/MINMON	228
The PNPLA3 genotype is the main driver of weight gain after the hepatitis C cure	223
Oral antibiotic treatment protects mice against the development of diet-induced non-alcoholic fatty liver disease but not against diet-induced intestinal barrier dysfunction	219
The effects of a structured dietetics intervention in patients with non-alcoholic fatty liver disease	217
An explainable artificial intelligence model for prediction of high-risk non-alcoholic steatohepatitis	206

Policy and implementation needs for hepatitis B birth dose in the WHO African region: a survey of national program managers	205
Influence of language barrier and cultural differences in hepatitis B disease knowledge in the chinese community of Barcelona	201
Automation of hepatitis C screening through electronic health record algorithm	194
Hepatitis C seroconversion rates among individuals with repeated testing-Georgia, 2017–2021	191
Booster SARS-CoV-2 vaccination elicits robust antibody response to wild type but not Omicron subvariants BA.4/5 in patients with cirrhosis	187
Liver transplantation for patients with fibrolamellar hepatocellular carcinoma: a comprehensive multicenter analysis to support future decision making	186
A new nuclear-erythroid-2-related factor 2 activator for the treatment of non-alcoholic steatohepatitis: evidence of metabolic and anti-fibroinflammatory effects in human precision cut liver slices	186
Effect of housing temperature on non-alcoholic fatty liver disease development in C57BL/6N mice	185
Diagnostic accuracy of MRE for staging hepatic fibrosis in patients with NAFLD	184
Molecular epidemiology of hepatitis B virus and hepatitis delta virus coinfection in-Sudan	183
Platelet, elastography, age, sex and etiology for hepatocellular carcinoma surveillance in patients with advanced chronic liver disease: Please algorithm	173
Effectiveness and safety of conversion surgery for patients with initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitors: a real-world study	172
Hepatocyte senescence is linked with extrahepatic organ injury, failure of regeneration and mortality in patients with acute indeterminate hepatitis	172
Efficacy and tolerability of atezolizumab and bevacizumab in patients with hepatocellular carcinoma previously treated with systemic therapy: a global, observational study	165
Perturbation of rhythmicity of the circadian clock-oscillator in hepatic stellate cells is associated with liver fibrosis	162
Development of a high precision liver biopsy method to improve the accuracy of fibrosis staging and collagen profiling	162
Beneficial effect of cystic fibrosis transmembrane conductance regulator modulators on adults with cystic fibrosis liver disease	161
The discovery of AMS-I-1274, a high potent and orally active capsid-assembly modulator against hepatitis B virus	160
Evaluating pruritus and fatigue in patients with treatment-refractory primary biliary cholangitis	158
Diagnosis and pathophysiological analysis of sarcopenia using liver MR in chronic liver disease	158
Outcomes of pregnancy in patients with autoimmune hepatitis in the Netherlands	158
CyberLiver Animal Recognition Test (CL-ART): a novel remote monitoring tool to assess minimal hepatic encephalopathy	154
Safety and efficacy of the farnesoid X receptor (FXR) agonist cilofexor in a proof-of-concept study in patients with compensated cirrhosis due to primary sclerosing cholangitis (PSC)	154
Assessment of hepatic fibrosis screening in primary care using the FIB-4 score, followed in second line by an ELF (Enhanced liver Fibrosis) test	153
Sofosbuvir/Velpatasvir/Voxilaprevir for re-treatment in direct-acting antiviral experienced hepatitis C virus patients: a systematic review and meta-analysis	152
Durability of immune response to SARS-CoV-2 vaccination in patients with liver cirrhosis (LC) as compared to healthcare workers (HW)	151
Endoscopic glue injection v/s endoscopic human thrombin injection for bleeding gastric varics -a randomized controlled trial	149
Inclusion of the fatty liver-associated variants in the clinical workup of patients: results of an eight years’ experience in a tertiary referral center with genotyping facility	147
Neutrophil gelatinase-associated lipocalin predicts response to terlipressin and albumin in patients with hepatorenal syndrome	144
Bacterial infections in cirrhosis are associated with reduction in gut microbial phage-bacterial interactions	141
Humoral and cellular immune responses to SARS-CoV-2 vaccination across multiple vaccine platforms and liver disease types: an EASL registry multicentre prospective cohort study	141
Temporal trajectory of the model for end-stage liver disease (MELD) score for prediction of mortality among patients with liver cirrhosis	140
miR34a-5p is a target of E2F2 transcription factor in MAFLD-related HCC	140
TNFR1 inhibition reduces lipogenesis and improves insulin resistance and fibrosis in NAFLD	139
Association between liver cirrhosis and cardiovascular events in a large German cohort-a population based study	138
Toll-like receptor 5 signalling mediates pro-inflammatory and fibrogenic responses in non-alcoholic steatohepatitis (NASH)	138
Circadian sleep-wake rhythms in non-alcoholic fatty liver disease	134
Vitamin D deficiency associates with gut dysbiosis, endotoxemia and the risk of infectious complications in patients with liver cirrhosis	134
Liver Cancer Summit 2022 – Register before 23 December and take advantage of the early fees!	133
Portal venous branches as an anatomic railroad for a gut-bile duct-axis	131
Correspondence on “Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis”	130
Safety, pharmacokinetics, and antiviral activity of the S-antigen Transport Inhibiting Oligonucleotide Polymers (STOPS) drug candidate ALG-010133 in subjects with chronic hepatitis B	129
Reply to: Correspondence on “EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update”	127
THU-192 Liver steatosis assessed by controlled attenuation parameter in patients with primary biliary cholangitis	127
Corrigendum to “EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma” [J Hepatol (79) (2023) 181–208]	126
WED-347 Diagnosis of advanced liver fibrosis: the synergy of open data, synthetic data generation, CatBoost, and feature engineering	126
Is MASLD a real culprit for all-cause mortality? A meta-analysis and preliminary pathophysiology exploration in the real world	125
Combination of crafity score with alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma	123
Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis	121
MetALD accounts for a large part of what we call MASLD!	120

One stone, two birds: circACTN4, a nexus for a coordinated activation of Hippo and Wnt/β-catenin pathways in cholangiocarcinoma	120
Surgical treatment of intrahepatic cholangiocarcinoma	120
SAT-521 Impact of centre type on treatment and survival outcomes in hepatocellular carcinoma (HCC)	118
FRI-247 Association of plasma magnesium with MASH and cirrhosis: combined data from multiple therapeutic trials including more than 10, 000 patients	118
THU-457 Outcome of liver transplantation in patients with hepatocellular carcinoma previously treated with immune checkpoint inhibitorbased therapy-first results from an international multicenter regi	117
OS-077 Added value of a combination of positron emission tomography with 18F-FDG and 18 F-Fluorocholine for staging optimization and treatment modification in patients with hepatocellular carcinoma: t	116
FRI-195 Genetically determined circulating protein biomarkers and risk of advanced fibrosis	115
WED-257 FibroScan compared to liver biopsy for accurately detecting recurrent hepatic steatosis and fibrosis after liver transplantation for metabolic dysfunction-associated steatohepatitis	113
WED-092 Hyperuricemia leads to early cognitive dysfunction and neuronal cell injury in bile-duct ligated rats	111
THU-447 Incidence and predictors of complications following percutaneous liver biopsy: a multicenter study	111
WED-495 The impact of integration and decentralization of HBV services on enhancing the HBV care continuum: an interrupted time series	110
TOP-311-YI Subtypes of steatotic liver disease have differing clinical outcomes	110
FRI-475-YI NADPH oxidase 1 inhibition as therapeutic strategy in hepatocellular carcinoma: insights from human-relevant models	110
OS-004 Testing for hepatitis C virus infection in prisons in England: room for improvement	110
SAT-151-YI The role of interleukin-8 in primary sclerosing cholangitisassociated immune cell dysregulation	109
OS-111 Predictive genomic biomarkers for Atezolizumab plus Bevacizumab combination immunotherapy response in liver cancer: insights from the IMbrave150 trial	108
WED-058-YI High shear stress induced PIEZO1 activation promotes cytoskeleton remodelling and a nuclear deformation develops pro-thrombotic microenvironment and contributes to portal hypertension	108
SAT-479-YI Lower frequency of PNPLA3 in african populations and divergent associations with hepatocellular carcinoma	107
THU-099-YI Small duct primary sclerosing cholangitis is not associated with a heightened risk of colorectal cancer compared to inflammatory bowel disease alone	107
THU-219 Inhibition of HSD17B13 by INI-822 phenocopies the hepatic lipidomic profile of humans with the protective allele	106
SAT-070 Argon plasma coagulation or endoscopic band ligation for gastric antral vascular ectasia: a randomized comparative analysis	106
THU-114 Alkaline phosphatase levels at 6 months as a predictor of response to ursodeoxycholic acid at 1 year in patients with primary biliary cholangitis	105
FRI-457 CXCL12 restricts hepatocellular carcinoma progression by shaping the tumor microenvironment in liver fibrosis	104
THU-040-YI Establishment of the irish hepatology nurses association: an association for nurses working in liver disease in Ireland	103
SAT-009 Increased prevalence of metabolic-alcohol liver disease in Europe and of metabolic dysfunction-associated steatotic liver disease in the Americas. Results of the global IMPROVEMENT study	103
FRI-067 Impact of Farnesoid X receptor polymorphisms on prognosis in hepatocellular carcinoma	102
WED-524-YI Multi-omics study of chronic liver diseases with rifaximin treatment	102
FRI-245 Longitudinal follow-up of Fib-4 in patients at risk of steatotic liver disease (SLD) receiving low-dose Methotrexate treatment (LDMTX): results from the CIRT randomized placebo-controlled Tria	101
LBP-040 Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis (PBC): interimresults for 2 years from the ASSURE study	101
SAT-194 Effect of statin therapy in patients with obesity and cirrhosis secondary to metabolic dysfunction-associated steatotic liver disease (MASLD) on pre-liver transplant mortality	101
SAT-418 Prevalence of hepatitis C virus infection in a nursing home: a frequently overlooked submerged population	101
THU-093 Biochemical response and liver stiffness variation over time predict liver-related events in patients with primary biliary cholangitis treated with Obeticholic acid	100
WED-483 Performance comparison of four hepatitis E antibodies detection methods	100
LBP-016 Carvedilol versus propranolol in the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis	99
LBP-036 Final results from the phase 3 REGENERATE trial evaluating the effects of obeticholic acid in patients with pre-cirrhotic fibrosis due to metabolic dysfunction-associated steatohepatitis	99
SAT-041 Real-world evidence of magnesium isoglycyrrhizinate for perioperative protection against hepatic injury in patients undergoing hepatectomy	99
THU-405 Analysis of a decentralized model interdisciplinary for the elimination of HCV in vulnerable population in the province of Huelva (Spain). To continue advancing in the elimination of hepatitis	99
FRI-470 Deciphering the role of FXR in the rewiring of Treg polarization in hepatocellular carcinoma	99
WED-439 Linkage of anti‐HCV reactive persons to HCV care and treatment services in Georgia	98
WED-548 Rifaximin-alpha acts through increased abundance of Lactobacillus spp. in murine models of chronic liver disease	98
THU-087 Herpesvirus viremia-cause or consequence of ACLF? Higher prevalence of cytomegalovirus, Epstein-Barr virus and herpes simplex virus viremia in patients with acute-on-chronic liver failure	98
The impact of HCV cure on glycemic indices in patients using glecaprevir/pibrentasvir from nationwide Taiwan HCV registry	97
Sign up to EASL Campus: your open-access eLearning Hub	97
The impact of liver function improvement after direct-acting antiviral therapy on the outcome in hepatitis C virus patients with decompensated cirrhosis	96
Alcohol use disorder in patients undergoing bariatric surgery is associated with a worse prognosis	95
Lack of fibrosis remodelling in chronic hepatitis C post SVR, as demostrated by YKL-40, is predictive of hepatocellular carcinoma ocurrence	95
HCV micro-elimination strategy in a tertiary hospital: identification of lost cases and linkage to care	94
Full-length genome characterization of inherently resistant african HCV genotype 1, subtype 1l in patients failing DAA-based therapy	94
Novel anti-cholestatic treatment strategies by combining inhibition of the Apical sodium-dependent bile acid transporter with stimulation of urinary bile salt excretion or lowering bile salt synthesis	93
Gadoxetic acid-enhanced MRI-derived Functional Liver Imaging Score (FLIS) and spleen diameter provide complementary information for risk stratification in ACLD	93
Sofosbuvir/Velpatasvir (S/V) for the treatment of HCV infection among vulnerable inner-city residents: extending the results of clinical trial	92
Improvement of hepatic and extrahepatic functions and anti-inflammatory effects of nitazoxanide in disease models of LPS-induced systemic inflammation and acute-on-chronic liver failure	92
Disclosures: commercial relationships	92
Exacerbated response to patterned injury in the cirrhotic liver: potential susceptibility to ischemia	92
The regulatory protein and gene expression profile of skeletal muscle in chronic liver disease patients	92
HBsAg kinetics at month 9 after analogue treatment discontinuation in chronic hepatitis B eAg (-) predicts long-term HBV control	91
Feasibility of a home-based, virtually-delivered, group exercise intervention in older patients with liver cancer (TELEX-Liver Cancer)	91
Exploration of the lack of systematic surveillance for hepatocellular carcinoma for patients with non-alcoholic fatty liver disease	90
Combination of systemic immune-inflammation index and albumin-bilirubin score predict prognosis of sequential therapy with sorafenib and regorafenib in unresectable hepatocellular carcinoma	89
A gene editing approach for chronic hepatitis B: elimination of hepatitis B virus in vivo by targeting cccDNA and integrated viral genomes with a sequence-specific ARCUS nuclease	89
Online education significantly improved gastroenterologists’ knowledge of the diagnostic and monitoring techniques used in liver fibrosis	89
Association of liver fibrosis and hypophosphatemia in treatment-naïve patients with chronic hepatitis B	88
Dual effects of brown-fat activation limit hepatocellular carcinoma (HCC) progress in steatotic liver	88
Radiowater perfusion PETof the liver, and its value as a biomarker to discriminate between NAFLD and NASH, and activity and fibrosis grade	88
APRI+ALBI score is superior to Indocyanine Green (ICG) clearance and LiMAx test in the prediction of posthepatectomy liver failure-an international multicenter study of 14581 patients	87
HDV genotypes have an impact on pegylated interferon therapy response and long-term liver disease related outcomes	87
Reversal of epithelial-mesenchymal transition in a cholangiocarcinoma cell line by genetic targeting of sulfatide synthesis	86
Suboptimal virological response to antiviral therapy in chronic hepatitis B as an independent predictor for occurrence of HCC and development of severe liver events	86
Micro-elimination of chronic hepatitis C virus in patients with psychiatric disorders: a multidisciplinary strategy in the outpatient mental health center	86
Genetic modifiers of liver phenotypes in pediatric Wilson disease: liver biopsy and transient elastography based study	85
Estimating the prevalence of hepatitis delta infection among foreign-born adults with chronic hepatitis B in the United States	85
Sarcopenia at listing for liver transplantation is a negative predictor for post-transplant survival, but not for graft survival	84
Comparable risk of hepatocellular carcinoma between immune-tolerant and active phase in hepatitis B e antigen-positive patients	84
Acute liver failure due neonatal hemochromatosis: case with fatal outcome despite early diagnosis and treatment	84
Viral and ALT kinetics after nucleos (t)ide analogue withdrawal among patients who remain off-therapy: results from a global, multi-ethnic cohort of chronic hepatitis B patients (RETRACT-B study)	84
Factors associated with HCC stage at presentation and survival in an ethnically diverse UK population	83
No effect of HBsAg positivity on antibody response after COVID-19 vaccine	82
Immunogenicity and safety of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA SARS-CoV-2 vaccine in liver transplant recipients: a prospective study	82
HBV infection reshapes host chromatin accessibility and affects choline and iron metabolism	82
Effectiveness of MRI methods in the assessment of hepatic steatosis in living liver donors	81

Multi-omics profiling of cholangiocytes reveals sex-specific chromatin state dynamics during hepatic cystogenesis in polycystic liver disease	80
Production of reactive oxidant species and fatty acid uptake is increased in regulatory T-cells in autoimmune hepatitis, and associated with down-regulation of markers linked to suppressor function	80
Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients	79
Reply to: “Carvedilol in patients with compensated cirrhosis: The ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices”	79
Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients	79
Defining characteristics and outcomes for patients with non-alcoholic fatty liver disease admitted to hospital with decompensated cirrhosis	78
The space of Mall confirmed in humans: A response to “Portal venous branches as an anatomic railroad for a gut-bile duct axis”	78
Corrigendum to: ‘Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis’ [J Hepatol (2019) 722-734]	78
Submit your late-breaker abstract for the EASL Congress 2024 between 27 March - 10 April	78
Methodological challenges in studying immune-suppressive neutrophils in HCC models	77
A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Considerations	77
Digital pathology using stain-free imaging indices allows direct prediction of all-cause mortality, hepatic decompensation and hepatocellular carcinoma development in patients with non-alcoholic fatty	77
Genomics on the road to functional cure of hepatitis B	77
Reply to: “A comment on `A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B’”	77
Editorial Board	77
Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination	77
Discover the ILC 2021 Takeaways, discussions and debates around major ILC 2021 topics, coming in September	76
EASL Clinical Practice Guidelines on TIPS	76
Impact of alcohol on the progression of HCV-related liver disease: A systematic review and meta-analysis	76
PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial	76
Infection courses, virological features and IFN-α responses of HBV genotypes in cell culture and animal models	76
WED-519-YI Criss-cross fecal microbiota transplant identifies hepatic steroid biosynthesis and linoleic acid metabolism linked with liver injury and dysbiosis in rat	74
Lack of VMP1 impairs hepatic lipoprotein secretion and promotes non-alcoholic steatohepatitis	74
Differences between hepatocellular carcinoma caused by alcohol and other aetiologies	74
Direct reprogramming of somatic cells into induced hepatocytes: Cracking the Enigma code	73
THU-113 Optimizing thiopurine therapy in autoimmune hepatitis (AIH): a multi-center study on monitoring metabolite profiles and co-therapy with allopurinol	73
Falls are common, morbid, and predictable in patients with cirrhosis	73
Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score	72
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study	71
Hypoxia inducible factors regulate hepatitis B virus replication by activating the basal core promoter	70
Rethinking methodology and data integrity in Mendelian randomization: Insights from air pollution and MASLD research	70
RSK2 inactivation cooperates with AXIN1 inactivation or β-catenin activation to promote hepatocarcinogenesis	70
The multifactorial mechanisms of bacterial infection in decompensated cirrhosis	69
Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score	69
OS-124 Identification and validation of pre-identified morphological baseline features for prediction of fibrosis progression in MAESTRO-NASH	69
Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020	69
Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation	68
Primary hypocholesterolemia is associated with an increased risk of hepatic complications in the general population	67
Aberrant ubiquitination causing liver cancer: The ADRM1-ΔEx9- FBXW7 connection	67
Augmenter of liver regeneration: Mitochondrial function and steatohepatitis	67
Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease	67
Multimodal investigation of rat hepatitis E virus antigenicity: Implications for infection, diagnostics, and vaccine efficacy	67
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis	67
Dual and opposing roles of the androgen receptor in VETC-dependent and invasion-dependent metastasis of hepatocellular carcinoma	67
Visit EASL Campus & discover 4,100 + resources on hepatology & liver-related research	66
Changing epidemiology, global trends and implications for outcomes of NAFLD	66
Prediction of comprehensive prognosis through computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B	66
The composition of the bile acid pool is closely associated with fibrosis in the heart and liver of patients with cirrhosis	65
Combination therapy in HBeAg-negative chronic hepatitis B patients with low-level viremia to nucleos (tide) analogues	65
Treatment of chronic hepatitis B in sub-saharan Africa: 5-year results of a pilot program in Ethiopia	65
Generation of functional ductal organoid with biliary tree network in decelluarized liver scaffold	64
Opposite PAR2 roles in liver regeneration from autoimmune or direct damage. Solving the conflict	64
The devastating impact of severe pruritus in primary biliary cholangitis	64
High meat consumption is prospectively associated with non-alcoholic fatty liver disease and liver fibrosis markers	63
Hepatitis C screening program in Lithuania: first results and scenarios for virus elimination	63
Genetic risk of fatty liver disease and mortality in the general population	63
Deletion of ATR in hepatocytes improves NAFLD features by increasing mitochondrial function	62
Current prognosis of gastric variceal bleeding in France: preliminary results from a multicenter prospective cohort of 87 cirrhotic patients	62
Exposure to the SARS-CoV-2 spike protein in an in vitro model of steatosis enhances hepatocyte oxidative stress: implications for COVID-19 and accelerated disease progression	61
The impact of Clostridium difficile on mortality and outcomes in patients with NAFLD vs. NASH	61
Intrahepatic microcirculation disorders and hyperammoniemia and their correction at non-alcoholic steatohepatitis patients with initial stages of liver fibrosis	61
Evaluation of semisynthetic high-fat diets in development of a 4-week mouse NASH model	61
Hepatic steatosis in people with HIV is associated with lower BMI and more liver fibrosis compared to metabolic dysfunction-associated fatty liver disease	61
Role of the hepatocyte Epidermal Growth Factor Receptor (EGFR) pathway on the cellular interactome within the liver fibrotic niche	61
Sarcopenia is associated with the severity of metabolic associated fatty liver disease in elderly residents	61
HBV screening in west african migrant community and faith-based organizations increases HBV vaccination among this high-risk population in greater Barcelona, Spain	61
Prediction of ten-year risk of severe liver disease in the general population using commonly available biomarkers	60
Pyroptotic MAITs link microbial translocation with severity of alcohol-related liver disease	60
Control compounds used to validate in vitro models of idiosyncratic drug-induced liver injury: a systematic review	60
Risk factors for short-term post discharge clinical outcomes in patients hospitalized with decompensated chronic liver disease: interim results from Global CLEARED study	60
Dyserythropoiesis is underrecognized and contributes to severe anemia in liver cirrhosis	60
Direct-acting antiviral treatment in Albanian patients with chronic hepatitis C and advanced liver fibrosis	60
Treatment of hepatitis C in primary healthcare in the country of Georgia	59
Similar weight loss with semaglutide regardless of diabetes and cardiometabolic parameters in individuals with non-alcoholic fatty liver disease	59
Obeticholic acid administration increases hepatic eNOS levels counteracting lipid accumulation and fibrosis in a diet-induced ob/ob mouse model of NASH	59
Peculiar monocyte bioenergetic profile in non-alcoholic steatohepatitis (NASH)	58
Hepatocellular carcinoma and neutrophils-towards understanding positive and negative impacts on treatments and progression	58
Uncovering the role of ISOC1 in non-alcoholic fatty liver disease	58
Six-fold increased rate of chronic kidney disease after acute kidney injury: a population-based cohort study of 46,946 patients with cirrhosis	58
In-depth shotgun metagenomic analysis of the oral and gut microbiome identifies striking overlap in microbial community structure, virulence factors and antimicrobial resistance genes based on stage a	58
Non-invasive diagnosis of clinically significant portal hypertension and treatment with non-selective beta-blockers: a new paradigm	58
Extracellular vesicles carrying oxidation-specific epitopes as effectors in acute hepatic decompensation and acute-on-chronic liver failure-a pilot study	58
Influence of comorbidities and lifestyle factors on health-related quality of life in alcohol-related liver disease: a population-based survey	58
Reduced hepatic expression of PPAR alpha in primary biliary cirrhosis is modulated by miR-155	57
Prognostic impact of variants in TM6SF2 and MBOAT7 in patients who have progressed to advanced chronic liver disease	57
Biliary epithelial cell-specific RAGE controls ductular reaction-mediated fibrosis during cholestasis	57
The growing global burden of non-alcoholic fatty liver disease (NAFLD) among teenagers	56
A derivation and validation study of paired liver and plasma proteomics in 659 individuals reveals circulating biomarkers for alcohol-related liver disease	56
One-step diagnosis: detection and stratification of incidental hepatic steatosis by multiparametric abdominal ultrasound	56
Significantly higher clinical and economic burden following diagnosis of hepatitis delta virus infection among commercially insured adults with chronic hepatitis B in the United States	56
Implementing a clinical care algorithm for screening of liver fibrosis in specialist diabetes care	56
3D human NASH model as a screening-based discovery approach for selecting and prioritizing drug candidates	56
Long-term safety profile of tenofovir alafenamide in chronic hepatitis B patients; final 8-year results of 2 Phase 3 studies	55
Public knowledge and attitudes toward liver diseases and liver cancer in the brazilian population	55
Evaluation of non-invasive tests to identify precirrhotic fibrosis due to NASH in patients screened for the phase 3 REGENERATE and REVERSE studies of obeticholic acid	55